New Zealand markets closed

Clover Biopharmaceuticals, Ltd. (2197.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
0.455+0.015 (+3.41%)
As of 11:41AM HKT. Market open.
Full screen
Previous close0.440
Open0.450
Bid0.450 x N/A
Ask0.455 x N/A
Day's range0.430 - 0.455
52-week range0.390 - 2.850
Volume503,000
Avg. volume2,184,084
Market cap588.802M
Beta (5Y monthly)3.91
PE ratio (TTM)N/A
EPS (TTM)-0.710
Earnings date21 Mar 2024 - 22 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.99
  • PR Newswire

    Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)

    Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company, today announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase Ⅰ clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).

  • PR Newswire

    Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate

    Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company's RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover's Trimer-Tag vaccine technology platform.

  • PR Newswire

    Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil

    Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the company completes the Biologic License Application (BLA) submission for its seasonal influenza vaccine (AdimFlu-S) to Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, or ANVISA). Upon approval, Clover will work with its local partner to com